PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDeuruxolitinib
Deuruxolitinib
Leqselvi (deuruxolitinib) is a small molecule pharmaceutical. Deuruxolitinib was first approved as Leqselvi on 2024-07-25. The pharmaceutical is active against tyrosine-protein kinase JAK2 and tyrosine-protein kinase JAK1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Leqselvi
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Deuruxolitinib phosphate
Tradename
Company
Number
Date
Products
LEQSELVISun Pharmaceutical IndustriesN-217900 RX2024-07-25
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
leqselviNew Drug Application2025-07-17
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
alopecia areataEFO_0004192D000506L63
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
24 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Alopecia areataD000506EFO_0004192L63—13——3
AlopeciaD000505—L64——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDeuruxolitinib
INNdeuruxolitinib
Description
Deuruxolitinib (CTP-543) is a Janus kinase inhibitor selective for JAK1 and JAK2. It is in development to treat alopecia areata. If approved the drug would compete with others with a similar mechanism of action developed by Eli Lilly and Pfizer.
Classification
Small molecule
Drug classdeuterated compounds; tyrosine kinase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
[2H]C1([2H])C([C@@H](CC#N)n2cc(-c3ncnc4[nH]ccc34)cn2)C([2H])([2H])C([2H])([2H])C1([2H])[2H]
Identifiers
PDB—
CAS-ID1513883-39-0
RxCUI—
ChEMBL IDCHEMBL4594381
ChEBI ID—
PubChem CID72704611
DrugBankDB18847
UNII ID0CA0VSF91Y (ChemIDplus, GSRS)
Target
Agency Approved
JAK2
JAK2
JAK1
JAK1
Organism
Homo sapiens
Gene name
JAK2
Gene synonyms
NCBI Gene ID
3717
Protein name
tyrosine-protein kinase JAK2
Protein synonyms
JAK-2, Janus kinase 2, Janus kinase 2 (a protein tyrosine kinase)
Uniprot ID
O75297
Mouse ortholog
Jak2 (16452)
tyrosine-protein kinase JAK2 (Q7TQD0)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 76 documents
View more details
Safety
Black-box Warning
Black-box warning for: Leqselvi
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use